World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
136
Citations
68172
World Ranking
1981
National Ranking
1124

Research.com Recognitions

  • 2013 - Fellow of the American Association for the Advancement of Science (AAAS)
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Carlos L. Arteaga is affiliated with The University of Texas Southwestern Medical Center in the United States. Their research spans a wide range of topics primarily focused on cancer, with significant contributions to oncology, molecular biology, and pulmonary and respiratory medicine within the broader field of medicine.

The scientist's main fields of study include Medicine with 299 publications and Biochemistry, Genetics, and Molecular Biology with 146 publications. Subfields of study prominently feature Oncology with 124 publications, Pulmonary and Respiratory Medicine with 86, Molecular Biology with 70, Cancer Research with 51, and Radiology, Nuclear Medicine and Imaging with 29.

Key topics addressed in their research involve Advanced Breast Cancer Therapies (114 publications), HER2/EGFR in Cancer Research (72), Cancer Genomics and Diagnostics (58), Breast Cancer Treatment Studies (36), Monoclonal and Polyclonal Antibodies Research (30), Fibroblast Growth Factor Research (30), and Cancer Treatment and Pharmacology (28).

The scientist has contributed extensively to several publication venues. Frequent venues include Cancer Research with 52 publications, Journal of Clinical Oncology and Clinical Cancer Research each with 15 publications, JCO Precision Oncology with 11, and Annals of Oncology with 7.

Frequent coauthors include Ariella B. Hanker (64 joint publications), Keith T. Flaherty (41), Lyndsay N. Harris (41), Robert J. Gray (39), and Lisa M. McShane (39), indicating collaborative work within notable cancer research networks.

Selected recent publications include:

  • Overcoming Endocrine Resistance in Breast Cancer, 2020, Cancer Cell
  • Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH), 2020, Journal of Clinical Oncology
  • Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H, 2020, Journal of Clinical Oncology
  • The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design, 2020, JNCI Journal of the National Cancer Institute
  • Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab, 2021, Cancer Discovery

Their recognitions include being named a Fellow of the American Association for the Advancement of Science (AAAS) in 2013 and membership in the Association of American Physicians.

Best Publications

  • Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

    Gabriel N. Hortobagyi;Salomon M. Stemmer;Howard A. Burris;Yoon-Sim Yap

  • Transforming Growth Factor-β1 Mediates Epithelial to Mesenchymal Transdifferentiation through a RhoA-dependent Mechanism

    Neil A. Bhowmick;Mayshan Ghiassi;Andrei Bakin;Mary Aakre

  • Phosphatidylinositol 3-Kinase Function Is Required for Transforming Growth Factor β-mediated Epithelial to Mesenchymal Transition and Cell Migration

    Andrei V. Bakin;Anne K. Tomlinson;Neil A. Bhowmick;Harold L. Moses

  • ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.

    Carlos L. Arteaga;Jeffrey A. Engelman

  • Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer

    José Baselga;Carlos L. Arteaga

  • Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method.

    S. B. Heymsfield;C. Arteaga;C. M. McManus;J. Smith

  • Treatment of HER2-positive breast cancer: current status and future perspectives

    Carlos L. Arteaga;Mark X. Sliwkowski;C. Kent Osborne;Edith A. Perez

  • PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.

    Incheol Shin;F. Michael Yakes;Federico Rojo;Nah young Shin

  • The PI3K/AKT Pathway as a Target for Cancer Treatment.

    Ingrid A. Mayer;Carlos L. Arteaga

  • Herceptin-induced Inhibition of Phosphatidylinositol-3 Kinase and Akt Is Required for Antibody-mediated Effects on p27, Cyclin D1, and Antitumor Action

    F. Michael Yakes;Wichai Chinratanalab;Christoph A. Ritter;Walter King

  • Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

    Gabriel N. Hortobagyi;Salomon M. Stemmer;Howard A. Burris;Yoon-Sim Yap

  • Epidermal Growth Factor Receptor (HER1) Tyrosine Kinase Inhibitor ZD1839 (Iressa) Inhibits HER2/neu (erbB2)-overexpressing Breast Cancer Cells in Vitro and in Vivo

    Stacy L. Moulder;F. Michael Yakes;Senthil K. Muthuswamy;Roberto Bianco

  • HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

    David M. Hyman;Sarina A. Piha-Paul;Helen Won;Jordi Rodon

  • Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.

    Christoph A. Ritter;Marianela Perez-Torres;Cammie Rinehart;Marta Guix

  • Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases

    Rebecca S. Muraoka;Nancy Dumont;Christoph A. Ritter;Teresa C. Dugger

  • Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor positive breast cancer

    Rinath Jeselsohn;Roman Yelensky;Gilles Buchwalter;Gilles Buchwalter;Garrett Frampton

  • Epidermal Growth Factor Receptor Dependence in Human Tumors: More Than Just Expression?

    Carlos L. Arteaga

  • Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.

    Marta Guix;Anthony C. Faber;Shizhen Emily Wang;Maria Graciela Olivares

  • TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer

    Neil E. Bhola;Justin M. Balko;Teresa C. Dugger;María Gabriela Kuba

  • Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer

    Todd W. Miller;Bryan T. Hennessy;Ana M. González-Angulo;Emily M. Fox

Frequent Co-Authors

Justin M. Balko
Justin M. Balko Vanderbilt University Medical Center
Ingrid A. Mayer
Ingrid A. Mayer Vanderbilt University Medical Center
Eric P. Winer
Eric P. Winer Yale University
José Baselga
José Baselga Memorial Sloan Kettering Cancer Center
Gordon B. Mills
Gordon B. Mills Oregon Health & Science University
Keith T. Flaherty
Keith T. Flaherty Harvard University
Stanley R. Hamilton
Stanley R. Hamilton City Of Hope National Medical Center
Peter J. O'Dwyer
Peter J. O'Dwyer University of Pennsylvania
Ana M. Gonzalez-Angulo
Ana M. Gonzalez-Angulo The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in medicine or healthcare, there are a variety of related online degree programs that can complement or offer alternative pathways to traditional medical school.

For those drawn to nutrition, online nutrition degrees allow you to build a science foundation and specialize in wellness or dietetics, all from home.

If you’re interested in leadership or hospital management, learn how to evaluate healthcare administration degree programs to ensure accreditation and career readiness.

Nurses seeking to advance without interrupting their work can look for rn to bsn with no clinicals options, which allow flexibility by omitting on-site clinical requirements.

For those aiming for the highest level in nursing, accelerated dnp programs online offer a fast-track to a Doctor of Nursing Practice degree, shortening your time to leadership roles.

Exploring these online pathways can help you find the right program tailored to your interests, lifestyle, and career ambitions within healthcare.

Best Scientists Citing Carlos L. Arteaga

Trending Scientists

Recently Published Articles